Radioimmunoimaging of AL Amyloidosis
| Status: | Completed |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 9/23/2012 |
| Start Date: | November 2008 |
| End Date: | February 2012 |
| Contact: | Alan Solomon, MD |
| Email: | asolomon@utmck.edu |
| Phone: | (865) 305-9167 |
Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive
monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT
imaging in patients with AL amyloidosis.
To be eligible for this study, patients must have a confirmed diagnosis of AL amyloidosis
without significant cardiac (New York Heart Association class IV) disease and not be on
kidney dialysis. Additionally, after testing, their blood must not contain antibodies to
mouse proteins. The study requires an intravenous infusion, over 10 minutes, of the
radiolabeled antibody, followed 48 hours later by a PET/CT scan. A repeat scan is done 5 or
7 days after infusion of the antibody. A 5 ml blood specimen needs to be furnished 4 and 8
weeks after the antibody infusion.
Inclusion Criteria:
- Confirmed diagnosis of AL Amyloidosis
Exclusion Criteria:
- New York Heart Association class IV
- patient on renal dialysis
- serum antibodies to mouse protein
We found this trial at
1
site
Click here to add this to my saved trials
